Use of agent-based simulations to design and interpret HIV clinical trials

Diego F. Cuadros, Laith Aburaddad, Susanne Awad, Gisela García-Ramos

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In this study, we illustrate the utility of an agent-based simulation to inform a trial design and how this supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV Transmission Study. We simulated a variation of this study using valacyclovir therapy as the intervention, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results indicate that a small fraction (20%) of the simulated Partners in Prevention HSV/HIV Transmission Study realizations rejected the null hypothesis, which was no effect from the intervention. Our results also suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2 suppression (valacyclovir therapy) is more likely to identify the efficacy of the intervention. For the male circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major fraction (81%) of RCT realizations' that rejects the null hypothesis, which was no effect from the intervention. Our study highlights how agent-based simulations synthesize individual variation in the epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs aimed at evaluating combination prevention interventions in community-based RCTs, wherein an intervention[U+05F3]s effectiveness is challenging to predict.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalComputers in Biology and Medicine
Volume50
DOIs
Publication statusPublished - 1 Jul 2014
Externally publishedYes

Fingerprint

Randomized Controlled Trials
Clinical Trials
HIV
Male Circumcision
valacyclovir
Human Herpesvirus 2
Therapeutics
Pharmaceutical Preparations

Keywords

  • Agent-based simulation
  • Clinical trial
  • HIV
  • HIV treatment and prevention
  • Mathematical modeling

ASJC Scopus subject areas

  • Computer Science Applications
  • Health Informatics
  • Medicine(all)

Cite this

Use of agent-based simulations to design and interpret HIV clinical trials. / Cuadros, Diego F.; Aburaddad, Laith; Awad, Susanne; García-Ramos, Gisela.

In: Computers in Biology and Medicine, Vol. 50, 01.07.2014, p. 1-8.

Research output: Contribution to journalArticle

@article{d14d46a90c864e91852c76aa8a750635,
title = "Use of agent-based simulations to design and interpret HIV clinical trials",
abstract = "In this study, we illustrate the utility of an agent-based simulation to inform a trial design and how this supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV Transmission Study. We simulated a variation of this study using valacyclovir therapy as the intervention, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results indicate that a small fraction (20{\%}) of the simulated Partners in Prevention HSV/HIV Transmission Study realizations rejected the null hypothesis, which was no effect from the intervention. Our results also suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2 suppression (valacyclovir therapy) is more likely to identify the efficacy of the intervention. For the male circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major fraction (81{\%}) of RCT realizations' that rejects the null hypothesis, which was no effect from the intervention. Our study highlights how agent-based simulations synthesize individual variation in the epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs aimed at evaluating combination prevention interventions in community-based RCTs, wherein an intervention[U+05F3]s effectiveness is challenging to predict.",
keywords = "Agent-based simulation, Clinical trial, HIV, HIV treatment and prevention, Mathematical modeling",
author = "Cuadros, {Diego F.} and Laith Aburaddad and Susanne Awad and Gisela Garc{\'i}a-Ramos",
year = "2014",
month = "7",
day = "1",
doi = "10.1016/j.compbiomed.2014.03.008",
language = "English",
volume = "50",
pages = "1--8",
journal = "Computers in Biology and Medicine",
issn = "0010-4825",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Use of agent-based simulations to design and interpret HIV clinical trials

AU - Cuadros, Diego F.

AU - Aburaddad, Laith

AU - Awad, Susanne

AU - García-Ramos, Gisela

PY - 2014/7/1

Y1 - 2014/7/1

N2 - In this study, we illustrate the utility of an agent-based simulation to inform a trial design and how this supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV Transmission Study. We simulated a variation of this study using valacyclovir therapy as the intervention, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results indicate that a small fraction (20%) of the simulated Partners in Prevention HSV/HIV Transmission Study realizations rejected the null hypothesis, which was no effect from the intervention. Our results also suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2 suppression (valacyclovir therapy) is more likely to identify the efficacy of the intervention. For the male circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major fraction (81%) of RCT realizations' that rejects the null hypothesis, which was no effect from the intervention. Our study highlights how agent-based simulations synthesize individual variation in the epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs aimed at evaluating combination prevention interventions in community-based RCTs, wherein an intervention[U+05F3]s effectiveness is challenging to predict.

AB - In this study, we illustrate the utility of an agent-based simulation to inform a trial design and how this supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV Transmission Study. We simulated a variation of this study using valacyclovir therapy as the intervention, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results indicate that a small fraction (20%) of the simulated Partners in Prevention HSV/HIV Transmission Study realizations rejected the null hypothesis, which was no effect from the intervention. Our results also suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2 suppression (valacyclovir therapy) is more likely to identify the efficacy of the intervention. For the male circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major fraction (81%) of RCT realizations' that rejects the null hypothesis, which was no effect from the intervention. Our study highlights how agent-based simulations synthesize individual variation in the epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs aimed at evaluating combination prevention interventions in community-based RCTs, wherein an intervention[U+05F3]s effectiveness is challenging to predict.

KW - Agent-based simulation

KW - Clinical trial

KW - HIV

KW - HIV treatment and prevention

KW - Mathematical modeling

UR - http://www.scopus.com/inward/record.url?scp=84899819559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899819559&partnerID=8YFLogxK

U2 - 10.1016/j.compbiomed.2014.03.008

DO - 10.1016/j.compbiomed.2014.03.008

M3 - Article

VL - 50

SP - 1

EP - 8

JO - Computers in Biology and Medicine

JF - Computers in Biology and Medicine

SN - 0010-4825

ER -